Renaissance Technologies (RenTech)'s PTCT Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 533,300 shares of PTC Therapeutics, Inc. (PTCT) worth $36.33 M, representing 0.06% of the portfolio. First purchased in 2014-Q2, this long-term strategic position has been held for 38 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in PTCT, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2016, adding 948,700 shares. Largest reduction occurred in Q2 2016, reducing 846,800 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s PTC Therapeutics (PTCT) Holding Value Over Time
Track share changes against reported price movement
Quarterly PTC Therapeutics (PTCT) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -74,289 | Reduce 12.23% | 533,300 | $68.13 |
| Q4 2025 | -319,711 | Reduce 34.48% | 607,589 | $75.96 |
| Q3 2025 | -36,000 | Reduce 3.74% | 927,300 | $61.37 |
| Q2 2025 | +293,100 | Add 43.73% | 963,300 | $48.84 |
| Q1 2025 | +17,100 | Add 2.62% | 670,200 | $50.96 |
| Q4 2024 | +114,900 | Add 21.35% | 653,100 | $45.14 |
| Q3 2024 | -279,900 | Reduce 34.21% | 538,200 | $37.10 |
| Q2 2024 | +56,700 | Add 7.45% | 818,100 | $30.58 |
| Q1 2024 | +138,500 | Add 22.23% | 761,400 | $29.09 |
| Q4 2023 | +388,300 | Add 165.52% | 622,900 | $27.56 |
| Q3 2023 | +234,600 | New Buy | 234,600 | $22.41 |
| Q4 2022 | -5,600 | Sold Out | 0 | $0.00 |
| Q3 2022 | +5,600 | New Buy | 5,600 | $50.18 |
| Q1 2022 | -22,000 | Sold Out | 0 | $0.00 |
| Q4 2021 | -59,600 | Reduce 73.04% | 22,000 | $39.82 |
| Q3 2021 | -123,410 | Reduce 60.20% | 81,600 | $37.21 |
| Q2 2021 | +13,810 | Add 7.22% | 205,010 | $42.27 |
| Q1 2021 | +191,200 | New Buy | 191,200 | $47.35 |
| Q3 2020 | -5,200 | Sold Out | 0 | $0.00 |
| Q2 2020 | -374,200 | Reduce 98.63% | 5,200 | $50.77 |
| Q1 2020 | +65,500 | Add 20.87% | 379,400 | $44.61 |
| Q4 2019 | +183,600 | Add 140.91% | 313,900 | $48.03 |
| Q3 2019 | -238,760 | Reduce 64.69% | 130,300 | $33.82 |
| Q2 2019 | -538,240 | Reduce 59.32% | 369,060 | $45.00 |
| Q1 2019 | -115,400 | Reduce 11.28% | 907,300 | $37.64 |
| Q4 2018 | +740,100 | Add 261.89% | 1.02 M | $34.32 |
| Q3 2018 | +282,600 | New Buy | 282,600 | $47.00 |
| Q2 2018 | -219,200 | Sold Out | 0 | $0.00 |
| Q1 2018 | -7,400 | Reduce 3.27% | 219,200 | $27.06 |
| Q4 2017 | +226,600 | New Buy | 226,600 | $16.68 |
| Q4 2016 | -552,700 | Sold Out | 0 | $0.00 |
| Q3 2016 | +450,800 | Add 442.39% | 552,700 | $14.01 |
| Q2 2016 | -846,800 | Reduce 89.26% | 101,900 | $7.02 |
| Q1 2016 | +948,700 | New Buy | 948,700 | $6.44 |
| Q4 2015 | -65,900 | Sold Out | 0 | $0.00 |
| Q3 2015 | +65,900 | New Buy | 65,900 | $26.71 |
| Q3 2014 | -21,600 | Sold Out | 0 | $0.00 |
| Q2 2014 | +21,600 | New Buy | 21,600 | $26.16 |
Renaissance Technologies (RenTech)'s PTC Therapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased PTC Therapeutics, Inc. (PTCT) in Q2 2014, acquiring 21,600 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held PTC Therapeutics, Inc. (PTCT) for 38 quarters since Q2 2014.
Renaissance Technologies (RenTech)'s largest addition to PTC Therapeutics, Inc. (PTCT) was in Q1 2016, adding 948,700 shares worth $6.11 M.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 533,300 shares of PTC Therapeutics, Inc. (PTCT), valued at approximately $36.33 M.
As of the Q1 2026 filing, PTC Therapeutics, Inc. (PTCT) represents approximately 0.06% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in PTC Therapeutics, Inc. (PTCT) was 1,022,700 shares, as reported at the end of Q4 2018.